Correlation Between Mineralys Therapeutics, and Bicycle Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Bicycle Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Bicycle Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Bicycle Therapeutics, you can compare the effects of market volatilities on Mineralys Therapeutics, and Bicycle Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Bicycle Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Bicycle Therapeutics.

Diversification Opportunities for Mineralys Therapeutics, and Bicycle Therapeutics

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Mineralys and Bicycle is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Bicycle Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bicycle Therapeutics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Bicycle Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bicycle Therapeutics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Bicycle Therapeutics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Bicycle Therapeutics

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.45 times more return on investment than Bicycle Therapeutics. However, Mineralys Therapeutics, Common is 2.22 times less risky than Bicycle Therapeutics. It trades about -0.02 of its potential returns per unit of risk. Bicycle Therapeutics is currently generating about -0.16 per unit of risk. If you would invest  1,255  in Mineralys Therapeutics, Common on October 5, 2024 and sell it today you would lose (30.00) from holding Mineralys Therapeutics, Common or give up 2.39% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Mineralys Therapeutics, Common  vs.  Bicycle Therapeutics

 Performance 
       Timeline  
Mineralys Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Bicycle Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bicycle Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Mineralys Therapeutics, and Bicycle Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mineralys Therapeutics, and Bicycle Therapeutics

The main advantage of trading using opposite Mineralys Therapeutics, and Bicycle Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Bicycle Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bicycle Therapeutics will offset losses from the drop in Bicycle Therapeutics' long position.
The idea behind Mineralys Therapeutics, Common and Bicycle Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements